angiotensin receptor blocker – Page 8 – Communicable Diseases Research

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients

Research Article

Published on 2021-01-252022-10-28
Journal: BMC Infectious Diseases [Category] COVID-19,

Risk Factors for Development of Acute Kidney Injury in COVID-19 Patients: A Retrospective Observational Cohort Study

Observational Study

Published on 2021-01-012022-10-05
Journal: Nephron [Category] 임상,

[키워드] 95% confidence interval acute renal failure adjusted odds ratio age AKI Analysis angiotensin receptor blocker angiotensin-converting enzyme inhibitor Appropriate ARB association avoidance baseline Charlson Comorbidity Index chronic Chronic kidney disease Comorbidity condition coronavirus infection disease COVID-19 COVID-19 patient COVID-19 severity Creatinine. criteria development disease severity dominance evaluate Factor Factors highest hospital hypoxia Improving increased risk interquartile range kidney Kidney injury male multivariable logistic regression nonsteroidal anti-inflammatory drug NSAID NSAIDS occurred Patient patients with COVID-19 predicted predictor premorbid Prevent renal retrospective risk factor Seven severe COVID-19 Singapore was performed was used
[DOI] 10.1159/000514064 PMC 바로가기 [Article Type] Observational Study

Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study

Observational Study

Published on 2021-01-012022-10-05
Journal: Journal of clinical hypertension (Greenwich, Conn. [Category] SARS, 임상,

[키워드] 95% CI age analyses angiotensin receptor blocker Angiotensin receptor blockers Angiotensin-converting enzyme angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitors anticoagulant medication ARB association Beta blockers Cancer cardiovascular disease Comorbidity COVID-19 COVID-19 diagnosis defined diabete diagnosed with COVID-19 elevated evaluated exacerbate health condition Hospitalization hypertension increased risk individual inhibitor investigated less Massachusett medication medications mitigate modify Mortality outcomes Patient Prevent RAS receptor recommendation remains uncertain renin-angiotensin system risk SARS-COV-2 infection severe coronavirus disease severe COVID-19 severity Support Thiazide with COVID-19
[DOI] 10.1111/jch.14101 PMC 바로가기 [Article Type] Observational Study

The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities

신종 코로나바이러스 폐렴 및 기저 동반 질환의 치료에서 ACE2의 양방향 전환 역할

Review

Published on 2020-12-312022-09-10
Journal: Molecules [Category] MERS, SARS, 치료제,

[키워드] ACE ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 addition analyzed angiotensin angiotensin receptor blocker angiotensin-converting enzyme II (ACE2) anti-SARS-CoV-2 caused Comorbidities coronavirus disease Coronavirus disease 2019 Coronavirus pneumonia Coronavirus-2 COVID-19 described domain drug Drug discovery enzyme II epithelial cells functional globe higher affinity host cells hot spot hypertension Infection information inhibitor interact Intervention lung failure Lung injury membrane-bound Mortality Novel coronavirus novel coronavirus pneumonia Patient pharmacological Pneumonia potential treatment option Protein pulmonary epithelial cells RAS receptor receptor blocker recombinant ACE2 Renin renin-angiotensin system renin-angiotensin system (RAS) respiratory role SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 spike protein Severe acute respiratory syndrome Severe acute respiratory syndrome (SARS) severe acute respiratory syndrome Coronavirus Spike protein Spread suggested switch the SARS-CoV-2 therapeutic strategy Treatment Viral
[DOI] 10.3390/molecules26010142 PMC 바로가기 [Article Type] Review

Cognitive impact of COVID-19: looking beyond the short term

Review

Published on 2020-12-302022-10-28
Journal: Alzheimer's Research & Therapy [Category] COVID-19, MERS, SARS,

[키워드] accelerate accumulating ACE inhibitor ACE-2 acute illness angiotensin receptor blocker Angiotensin receptor blockers Angiotensin-converting enzyme angiotensin-converting enzyme inhibitors angiotensin-converting enzyme-2 ApoE cardiorespiratory Central nervous system cerebral classical CNS Cognitive function Cognitive impairment COVID-19 COVID-19 patient current Dementia deplete develop disease Disseminated intravascular coagulation dysfunction Endothelial cell endothelial cells Evidence exacerbate exacerbating expression Follow-up hospitalised patient immune activation increased risk individuals infecting Inflammation inflammatory effect Lewy body Limited lowest medication Meta-analysis nasal mucosa Neurological complication neurons olfactory pathology Patient pericyte pericytes Phosphorylation predicted Protective RAS recent receptor reducing Respiratory disease Respiratory function risk SARS-CoV-2 SARS-CoV-2 entry SARS-CoV-2 virus Spread stroke suggested Survivors target therapy thrombosis vascular leakage vasculature virus White matter ischaemia
[DOI] 10.1186/s13195-020-00744-w PMC 바로가기 [Article Type] Review

Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

Research

Published on 2020-12-242022-10-05
Journal: Nature biotechnology [Category] SARS, 유전자 메커니즘, 치료법,

Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis

Articles

Published on 2020-12-172022-10-31
Journal: International Journal of Environmental Research an [Category] COVID-19,

[키워드] 95% CI ACEi ACEIs Acute kidney injury acute respiratory distress Affair Affect Algorithm analyses angiotensin receptor blocker approach ARB ARBs association baseline blocker calibrated CCBs center Characteristics clinically Cohort cohort analysis Columbia University Combination combination therapy Comparisons Control COVID-19 COVID-19 diagnosis COVID-19 in patient data-driven decrease defined demonstrated Department determine development diuretics Effects Electronic health record enzyme European experiment finding funding generalisability generate hazard ratio heterogeneity hospital Hospital admission hypertension identify increased risk inhibitor International IQVIA janssen Korean lower risk Medical Research Council medications meta-analysed Ministry of Health monotherapy negative control network no significant difference observational study Older outcome partnership Patient patient cohort Pneumonia receiving Registered renin–angiotensin system risk risk of COVID-19 Sepsis South Spain susceptibility syndrome System Treatment USA user veteran Welfare Wellcome Trust with COVID-19
[DOI] 10.1016/S2589-7500(20)30289-2 PMC 바로가기 [Article Type] Articles

Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease

Original Paper

Published on 2020-12-052022-10-31
Journal: Clinical Research in Cardiology [Category] COVID-19, COVID19(2023년), MERS, SARS,

Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology

Cardiovascular Medicine

Published on 2020-12-042022-10-31
Journal: Frontiers in Cardiovascular Medicine [Category] COVID-19,

[키워드] Abnormalities ACE2 ACEIs addition addressed angiotensin receptor blocker antibody ARBs Cancer cardio-oncology Cardiomyopathy cardiovascular disease Coagulopathy commonality coronavirus disease COVID-19 COVID-19 pandemic culprit virus CVD cytokine release Cytokine release syndrome drug Endothelial dysfunction enzyme equity Health Health disparities higher risk highlight human cell implementation IMPROVE Inflammation inhibitor Interaction Ischemia learning management Myopericarditis overlap pandemic pathophysiology Patient Perspective profile receptor right ventricle risk factor severe COVID-19 illness similarity Telemedicine Therapies Toxicity use of corticosteroids ventricular
[DOI] 10.3389/fcvm.2020.568720 PMC 바로가기 [Article Type] Cardiovascular Medicine

Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France

장기간 ACE 억제제/ARB 사용은 중증 COVID-19 환자의 중증 신장 기능 장애 및 급성 신장 손상과 관련이 있습니다: 프랑스 북동부의 추천 센터 코호트 결과

Article

Published on 2020-12-032022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 바이오마커,

[키워드] 95% CI 95% confidence interval ACE ACEi ACEi/ARB acute kidney Acute kidney injury Acute respiratory failure Analysis angiotensin angiotensin receptor blocker Angiotensin-converting enzyme angiotensin-converting enzyme inhibitor ARB association biochemical Biomarker center characteristic consecutive patient consecutive patients converting enzyme inhibitor coronavirus disease Coronavirus disease 2019 COVID-19 creatinine daily dose diagnosed disease Enzyme inhibitor evaluated France heart increase in increased risk independent predictors inflammatory reaction influence kidney Lisinopril liver dysfunction liver dysfunctions Logistic regression analysis longitudinal cohort study lung marker multivariable nitrogen Occurrence Odds ratio outcomes Patient patients performed phosphorus predict predictor receiver operating characteristic receptor receptor blocker Referral repeated measures Respiratory failure Result retrospective risk SARS-CoV-2 severe coronavirus disease severe COVID-19 severity treated urea urea nitrogen were assessed
[DOI] 10.1093/cid/ciaa677 PMC 바로가기 [Article Type] Article